A study by Barra et al. suggests that long-acting glucagon-like peptide-1 (GLP-1) analogues, which are used as a treatment for obesity, may help to restore natural killer (NK) cell function in people with obesity (PWO). In a study of 20 PWO, GLP-1 therapy was found to improve NK cell function, as measured by cytotoxicity and interferon-γ/granzyme B production, and increase a CD98-mTOR-glycolysis metabolic axis critical for NK cell cytokine production. These findings suggest that GLP-1 therapy could potentially contribute to the overall benefits of this class of medication beyond just weight loss.
Exciting breakthrough in cancer research! 🌟 Scientists have discovered a key link between cancer cells and replication stress, unveiling the role of Taurine Upregulated Gene 1 (TUG1). Targeting TUG1 with a drug, researchers developed TUG1-DDS, significantly controlling brain tumor growth in mice, particularly glioblastomas. Lead researcher Professor Yutaka Suzuki highlights the potential for therapeutic applications, […]
A new graphene sensor can detect COVID-19 and flu in 10 seconds and could be used to test for other respiratory infections as well. The sensor is made of graphene, a single layer of carbon atoms that is highly sensitive to the presence of viruses. It works by binding to antibodies that are specific to […]
Antarctica is experiencing profound changes, with flowering plants, moss, and algae spreading due to rising summer temperatures. Record-low sea ice levels have also been observed. In 2022, Antarctica saw its most significant heatwave on record, with temperatures reaching 39 °C above normal. Climate change amplified this event by 2°C over the last century, and projections […]